Drug Profile
E 7130
Alternative Names: E-7130Latest Information Update: 04 Aug 2023
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Developer Eisai Co Ltd; Harvard University
- Class Antineoplastics
- Mechanism of Action Endothelial cell modulators; Microtubule protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Breast cancer
Most Recent Events
- 04 Aug 2023 E 7130 is still in phase I trials for Solid tumours in Japan (IV, Infusion) (Eisai pipeline, August 2023)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Solid-tumours(Second-line therapy or greater) in Japan (IV, Infusion)
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Breast cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)